Pharmaceutical Industry News
Patent Cliff Pushes Pharma into Critical Situation
Saturday, 22, May 2010
More acquisitions are expected as the patent cliff pushes the pharmaceutical industry into a critical phase, with many executives believing that the industry will be unable to innovate sufficiently from within to replace blockbuster drugs.The findings come from a survey of 381 executives across the pharmaceutical and biotechnology sectors, conducted by Marks & Clerk, an international intellectual property group. Almost 70% of respondents forecast substantial acquisition activity to take place in the next two years, with 19% anticipating major activity within the next year.
Fortunately, the patent crisis has come at a time when the economic landscape is beginning to improve—more than 60% of respondents believe that the climate for doing business and access to funding have improved in the last 12 months."There has been a shift in concern from the global economic backdrop and the subsequent funding draught to more immediate industry-specific problems," Gareth Williams, a partner at Marks & Clerk, said in a press statement.